Literature DB >> 27592800

TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients.

Neha Jariwala1, Bernice Benoit2, Andrew V Kossenkov3, Landon K Oetjen4, Timothy M Whelan5, Christine M Cornejo2, Junko Takeshita2, Brian S Kim6, Louise C Showe3, Maria Wysocka7, Alain H Rook2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27592800      PMCID： PMC5358509          DOI： 10.1016/j.jid.2016.08.016

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  15 in total

1.  The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses.

Authors:  Robert J Johnston; Xin Yu; Jane L Grogan
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

2.  TIGIT Enhances Antigen-Specific Th2 Recall Responses and Allergic Disease.

Authors:  Evangelia Kourepini; Nikolaos Paschalidis; Davina C M Simoes; Maria Aggelakopoulou; Jane L Grogan; Vily Panoutsakopoulou
Journal:  J Immunol       Date:  2016-03-25       Impact factor: 5.422

Review 3.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

4.  Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells.

Authors:  Khalid Bin Dhuban; Eva d'Hennezel; Emil Nashi; Amit Bar-Or; Sadiye Rieder; Ethan M Shevach; Satoshi Nagata; Ciriaco A Piccirillo
Journal:  J Immunol       Date:  2015-03-11       Impact factor: 5.422

5.  FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.

Authors:  Julia B Heid; Angelika Schmidt; Nina Oberle; Sergij Goerdt; Peter H Krammer; Elisabeth Suri-Payer; Claus-Detlev Klemke
Journal:  J Invest Dermatol       Date:  2009-07-23       Impact factor: 8.551

6.  Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.

Authors:  Nicole Joller; Ester Lozano; Patrick R Burkett; Bonny Patel; Sheng Xiao; Chen Zhu; Junrong Xia; Tze G Tan; Esen Sefik; Vijay Yajnik; Arlene H Sharpe; Francisco J Quintana; Diane Mathis; Christophe Benoist; David A Hafler; Vijay K Kuchroo
Journal:  Immunity       Date:  2014-04-17       Impact factor: 31.745

7.  Helios Controls a Limited Subset of Regulatory T Cell Functions.

Authors:  Mathew Sebastian; Maria Lopez-Ocasio; Amina Metidji; Sadiye Amcaoglu Rieder; Ethan M Shevach; Angela M Thornton
Journal:  J Immunol       Date:  2015-11-18       Impact factor: 5.422

8.  Clinical significance of expanded Foxp3⁺ Helios⁻ regulatory T cells in patients with non-small cell lung cancer.

Authors:  Satoshi Muto; Yuki Owada; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Jun Osugi; Mika Hoshino; Mitsunori Higuchi; Hiroyuki Suzuki; Mitsukazu Gotoh
Journal:  Int J Oncol       Date:  2015-10-12       Impact factor: 5.650

9.  CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patients.

Authors:  Maria Wysocka; Andrew V Kossenkov; Bernice M Benoit; Andrea B Troxel; Elisha Singer; Andras Schaffer; Brian Kim; Tzvete Dentchev; Satoshi Nagata; Tomoko Ise; Louise C Showe; Alain H Rook
Journal:  J Invest Dermatol       Date:  2013-06-21       Impact factor: 8.551

Review 10.  Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.

Authors:  Isabelle Le Mercier; J Louise Lines; Randolph J Noelle
Journal:  Front Immunol       Date:  2015-08-21       Impact factor: 7.561
View more
  8 in total

1.  Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.

Authors:  Alyxzandria M Gaydosik; Tracy Tabib; Larisa J Geskin; Claire-Audrey Bayan; James F Conway; Robert Lafyatis; Patrizia Fuschiotti
Journal:  Clin Cancer Res       Date:  2019-04-22       Impact factor: 12.531

2.  High Expression of IKZF2 in Malignant T Cells Promotes Disease Progression in Cutaneous T Cell Lymphoma.

Authors:  Bufang Xu; Fengjie Liu; Yumei Gao; Jingru Sun; Yingyi Li; Yuchieh Lin; Xiangjun Liu; Yujie Wen; Shengguo Yi; Jingyang Dang; Ping Tu; Yang Wang
Journal:  Acta Derm Venereol       Date:  2021-12-07       Impact factor: 3.875

Review 3.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08

Review 4.  The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.

Authors:  Joseph S Durgin; David M Weiner; Maria Wysocka; Alain H Rook
Journal:  J Am Acad Dermatol       Date:  2020-12-22       Impact factor: 11.527

5.  Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes.

Authors:  Andrea M Moerman-Herzog; Daniel A Acheampong; Amanda G Brooks; Suzan M Blair; Ping-Ching Hsu; Henry K Wong
Journal:  Oncotarget       Date:  2019-08-20

6.  Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.

Authors:  Darci Phillips; Magdalena Matusiak; Belén Rivero Gutierrez; Salil S Bhate; Graham L Barlow; Sizun Jiang; Janos Demeter; Kimberly S Smythe; Robert H Pierce; Steven P Fling; Nirasha Ramchurren; Martin A Cheever; Yury Goltsev; Robert B West; Michael S Khodadoust; Youn H Kim; Christian M Schürch; Garry P Nolan
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

7.  CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.

Authors:  Jérôme Giustiniani; Gabor Dobos; Hélène Moins-Teisserenc; Tiago Eustaquio; Maxime Battistella; Nicolas Ortonne; Caroline Ram-Wolff; Jean-David Bouaziz; Anne Marie-Cardine; Samia Mourah; Martine Bagot; Thomas S Kupper; Rachael A Clark; Armand Bensussan; Adèle de Masson
Journal:  Blood Adv       Date:  2022-06-14

Review 8.  Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome.

Authors:  Andrea Moerman-Herzog; Syed J Mehdi; Henry K Wong
Journal:  Cells       Date:  2020-08-29       Impact factor: 6.600
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.